{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T15:30:17Z","timestamp":1786721417497,"version":"build-2736575974"},"reference-count":140,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,6,30]],"date-time":"2014-06-30T00:00:00Z","timestamp":1404086400000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.6061\/clinics\/2014(06)12","type":"journal-article","created":{"date-parts":[[2014,6,16]],"date-time":"2014-06-16T10:11:56Z","timestamp":1402913516000},"page":"438-446","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Pharmacological management of osteogenesis"],"prefix":"10.1016","volume":"69","author":[{"given":"Valeria","family":"Nardone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"D'Asta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Brandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.6061\/clinics\/2014(06)12_bib1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"issue":"12","key":"10.6061\/clinics\/2014(06)12_bib2","doi-asserted-by":"crossref","first-page":"5050","DOI":"10.1210\/endo.142.12.8536","article-title":"Minireview: the OPG\/RANKL\/RANK system","volume":"142","author":"Khosla","year":"2001","journal-title":"Endocrinology"},{"issue":"11","key":"10.6061\/clinics\/2014(06)12_bib3","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1161\/01.RES.0000149165.99974.12","article-title":"Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin","volume":"95","author":"Collin-Osdoby","year":"2004","journal-title":"Circ Res"},{"issue":"1-2","key":"10.6061\/clinics\/2014(06)12_bib4","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s10735-004-3839-1","article-title":"Detection of osteoprotegerin (OPG) and its ligand (RANKL) mRNA and protein in femur and tibia of the rat","volume":"36","author":"Silvestrini","year":"2005","journal-title":"J Mol Histol"},{"issue":"10","key":"10.6061\/clinics\/2014(06)12_bib5","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/nm.2452","article-title":"Evidence for osteocyte regulation of bone homeostasis through RANKL expression","volume":"17","author":"Nakashima","year":"2011","journal-title":"Nat Med"},{"issue":"7","key":"10.6061\/clinics\/2014(06)12_bib6","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1073\/pnas.96.7.3540","article-title":"Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand","volume":"96","author":"Hsu","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.6061\/clinics\/2014(06)12_bib7","first-page":"iv17","article-title":"Rebalancing bone turnover in favour of formation with strontium ranelate: Implications for bone strength","volume":"47 Suppl 4","author":"Fonseca","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.6061\/clinics\/2014(06)12_bib8","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/ar2165","article-title":"Biology of RANK, RANKL, and osteoprotegerin","volume":"9 Suppl 1","author":"Boyce","year":"2007","journal-title":"Arthritis Res Ther"},{"issue":"5-6","key":"10.6061\/clinics\/2014(06)12_bib9","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s001090100226","article-title":"Role of receptor activator of nuclear factor-kappa B ligand and osteopr otegerin in bone cell biology","volume":"79","author":"Hofbauer","year":"2001","journal-title":"J Mol Med"},{"issue":"6937","key":"10.6061\/clinics\/2014(06)12_bib10","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","article-title":"Osteoclast differentiation and activation","volume":"423","author":"Boyle","year":"2003","journal-title":"Nature"},{"issue":"4","key":"10.6061\/clinics\/2014(06)12_bib11","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jama.292.4.490","article-title":"Clinical implications of the osteoprotegerin\/RANKL\/RANK system for bone and vascular diseases","volume":"292","author":"Hofbauer","year":"2004","journal-title":"JAMA"},{"issue":"11","key":"10.6061\/clinics\/2014(06)12_bib12","first-page":"2016","article-title":"Clinical and biochemical response to single infusion of pamidronate in patients with active rheumatoid arthritis: a double blind placebo controlled study","volume":"21","author":"Eggelmeijer","year":"1994","journal-title":"J Rheumatol"},{"issue":"2","key":"10.6061\/clinics\/2014(06)12_bib13","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1651-2227.2000.tb01214.x","article-title":"Pamidronate treatment of bone fibrous dysplasia in nine children with McCune-Albright sindrome","volume":"89","author":"Lala","year":"2000","journal-title":"Acta Paediatr"},{"issue":"5484","key":"10.6061\/clinics\/2014(06)12_bib14","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1126\/science.289.5484.1508","article-title":"Therapeutic approaches to bone diseases","volume":"289","author":"Rodan","year":"2000","journal-title":"Science"},{"key":"10.6061\/clinics\/2014(06)12_bib15","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/00003086-200101000-00003","article-title":"Bisphosphonate therapy in fibrous dysplasia","volume":"382","author":"Lane","year":"2001","journal-title":"Clin Orthop"},{"issue":"12","key":"10.6061\/clinics\/2014(06)12_bib16","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1038\/sj.bjc.6600986","article-title":"Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro","volume":"88","author":"Tassone","year":"2003","journal-title":"Br J Cancer"},{"issue":"12 Suppl","key":"10.6061\/clinics\/2014(06)12_bib17","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1002\/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L","article-title":"Cellular and molecular mechanisms of action of bisphosphonates","volume":"88","author":"Rogers","year":"2000","journal-title":"Cancer"},{"issue":"4","key":"10.6061\/clinics\/2014(06)12_bib18","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/BF02547227","article-title":"The binding of pyrophosphate and two diphosphonates on hydroxyapatite crystals","volume":"11","author":"Jung","year":"1973","journal-title":"Calcif Tissue Res"},{"issue":"9 Pt 1","key":"10.6061\/clinics\/2014(06)12_bib19","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1177\/000348940311200907","article-title":"Zoledronic acid inhibits osteoclastogenesis in vitro and in a mouse model of inflammatory osteolysis","volume":"112","author":"Sudhoff","year":"2003","journal-title":"Ann Otol Rhinol Laryngol"},{"issue":"2","key":"10.6061\/clinics\/2014(06)12_bib20","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S8756-3282(03)00223-0","article-title":"Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis","volume":"33","author":"Evdokiou","year":"2003","journal-title":"Bone"},{"key":"10.6061\/clinics\/2014(06)12_bib21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1634\/theoncologist.9-90004-3","article-title":"Bisphosphonates: preclinical review","volume":"9 Suppl 4","author":"Green","year":"2004","journal-title":"Oncologist"},{"issue":"6","key":"10.6061\/clinics\/2014(06)12_bib22","doi-asserted-by":"crossref","first-page":"571","DOI":"10.2174\/1566524023362104","article-title":"Bisphosphonate mechanism of action","volume":"2","author":"Rodan","year":"2002","journal-title":"Curr Mol Med"},{"issue":"3","key":"10.6061\/clinics\/2014(06)12_bib23","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s004419900165","article-title":"Etidronate (HEBP) promotes osteoblast differentiation and wound closure in rat calvaria","volume":"302","author":"D'Aoust","year":"2000","journal-title":"Cell Tissue Res"},{"issue":"6","key":"10.6061\/clinics\/2014(06)12_bib24","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1172\/JCI114100","article-title":"Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow","volume":"83","author":"Hughes","year":"1989","journal-title":"J Clin Invest"},{"issue":"34","key":"10.6061\/clinics\/2014(06)12_bib25","doi-asserted-by":"crossref","first-page":"6941","DOI":"10.1016\/j.biomaterials.2005.04.059","article-title":"Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells","volume":"26","author":"Von Knoch","year":"2005","journal-title":"Biomaterials"},{"issue":"2","key":"10.6061\/clinics\/2014(06)12_bib26","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00223-001-2066-y","article-title":"Effects of risedronate, alendronate, and etidronate on the viability and activity of rat bone marrow stromal cells in vitro","volume":"72","author":"Still","year":"2003","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"10.6061\/clinics\/2014(06)12_bib27","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1023\/A:1014418017382","article-title":"Distinct mechanisms of bisphosphonate action between osteoblasts and breast cancer cells: identity of a potent new bisphosphonate analogue","volume":"71","author":"Reinholz","year":"2002","journal-title":"Breast Cancer Res Treat"},{"issue":"21","key":"10.6061\/clinics\/2014(06)12_bib28","first-page":"6001","article-title":"Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts","volume":"60","author":"Reinholz","year":"2000","journal-title":"Cancer Res"},{"issue":"5","key":"10.6061\/clinics\/2014(06)12_bib29","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1172\/JCI116422","article-title":"Bisphosphonates act on rat bone resorption through the mediation of osteoblasts","volume":"91","author":"Sahni","year":"1993","journal-title":"J Clin Invest"},{"issue":"1","key":"10.6061\/clinics\/2014(06)12_bib30","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/8756-3282(95)00426-2","article-title":"Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures","volume":"18","author":"Nishikawa","year":"1996","journal-title":"Bone"},{"issue":"10","key":"10.6061\/clinics\/2014(06)12_bib31","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1172\/JCI6800","article-title":"Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin","volume":"104","author":"Plotkin","year":"1999","journal-title":"J Clin Invest"},{"issue":"5","key":"10.6061\/clinics\/2014(06)12_bib32","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1067\/mlc.2000.109757","article-title":"Etidronate inhibits human osteoblast apoptosis by inhibition of pro-apoptotic factor(s) produced by activated T cells","volume":"136","author":"Y Abe","year":"2000","journal-title":"J Lab Clin Med"},{"issue":"1","key":"10.6061\/clinics\/2014(06)12_bib33","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1080\/030097498441155","article-title":"Bisphosphonates inhibit IL-6 production by human osteoblast-like cells","volume":"27","author":"Giuliani","year":"1998","journal-title":"Scand. J. Rheumatol"},{"issue":"1","key":"10.6061\/clinics\/2014(06)12_bib34","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejphar.2003.08.011","article-title":"Clodronate stimulates osteoblast differentiation in ST2 and MC3T3-E1 cells and rat organ cultures","volume":"477","author":"Itoh","year":"2003","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"10.6061\/clinics\/2014(06)12_bib35","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1006\/bbrc.2002.6510","article-title":"Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts","volume":"291","author":"Viereck","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"10.6061\/clinics\/2014(06)12_bib36","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1359\/jbmr.2004.19.1.147","article-title":"The nitrogencontaining bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblastlike cells by activating TNF-alpha converting enzyme (TACE)","volume":"19","author":"Pan","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"18","key":"10.6061\/clinics\/2014(06)12_bib37","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1016\/j.biomaterials.2003.11.024","article-title":"Osteoblast proliferation and maturation by bisphosphonates","volume":"25","author":"Im","year":"2004","journal-title":"Biomaterials"},{"issue":"2","key":"10.6061\/clinics\/2014(06)12_bib38","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1177\/147323000903700216","article-title":"Effects of alendronate on the proliferation and osteogenic differentiation of MG-63 cells","volume":"37","author":"Xiong","year":"2009","journal-title":"J Int Med Res"},{"issue":"5","key":"10.6061\/clinics\/2014(06)12_bib39","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S8756-3282(98)00033-7","article-title":"Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo","volume":"22","author":"Giuliani","year":"1998","journal-title":"Bone"},{"issue":"2","key":"10.6061\/clinics\/2014(06)12_bib40","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/(SICI)1097-4644(19980201)68:2<186::AID-JCB5>3.0.CO;2-R","article-title":"Structurally different bisphosphonates exert opposing effects on alkaline","volume":"68","author":"Klein","year":"1998","journal-title":"J Cell Biochem"},{"issue":"12","key":"10.6061\/clinics\/2014(06)12_bib41","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1007\/s11999-008-0409-y","article-title":"Alendronate enhances osteogenic differentiation of bone marrow stromal cells: a preliminary study","volume":"467","author":"Kim","year":"2009","journal-title":"Clin Orthop Relat Res"},{"issue":"1","key":"10.6061\/clinics\/2014(06)12_bib42","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.bone.2003.08.013","article-title":"The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of human bone-derived cells in vitro","volume":"34","author":"Pan","year":"2004","journal-title":"Bone"},{"issue":"3","key":"10.6061\/clinics\/2014(06)12_bib43","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00223-008-9104-y","article-title":"Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro","volume":"82","author":"Idris","year":"2008","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"10.6061\/clinics\/2014(06)12_bib44","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/jcb.21983","article-title":"Inhibition of osteoblast function in vitro by aminobisphosphonates","volume":"106","author":"Orriss","year":"2009","journal-title":"J Cell Biochem"},{"issue":"1","key":"10.6061\/clinics\/2014(06)12_bib45","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.bone.2010.08.008","article-title":"Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability","volume":"49","author":"Bellido","year":"2011","journal-title":"Bone"},{"issue":"18","key":"10.6061\/clinics\/2014(06)12_bib46","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"issue":"11","key":"10.6061\/clinics\/2014(06)12_bib47","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","article-title":"Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial","volume":"85","author":"Black","year":"2000","journal-title":"FIT Research Group. J Clin Endocrinol Metab"},{"issue":"5","key":"10.6061\/clinics\/2014(06)12_bib48","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group","volume":"344","author":"McClung","year":"2001","journal-title":"N Engl J Med"},{"issue":"14","key":"10.6061\/clinics\/2014(06)12_bib49","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"issue":"24","key":"10.6061\/clinics\/2014(06)12_bib50","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"issue":"5","key":"10.6061\/clinics\/2014(06)12_bib51","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.bone.2008.01.003","article-title":"Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis","volume":"42","author":"Rizzoli","year":"2008","journal-title":"Bone"},{"issue":"2","key":"10.6061\/clinics\/2014(06)12_bib52","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00198-010-1453-5","article-title":"Subtrochanteric fractures after long-term treatment with bisphosphonates: a european society on clinical and economic aspects of osteoporosis and osteoarthritis, and international osteoporosis foundation working group report","volume":"22","author":"Rizzoli","year":"2011","journal-title":"Osteoporos Int"},{"issue":"11","key":"10.6061\/clinics\/2014(06)12_bib53","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/jbmr.253","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research","volume":"25","author":"Shane","year":"2010","journal-title":"J Bone Miner Res"},{"issue":"3 Suppl","key":"10.6061\/clinics\/2014(06)12_bib54","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/cncr.11138","article-title":"A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases","volume":"97","author":"Body","year":"2003","journal-title":"Cancer"},{"issue":"10","key":"10.6061\/clinics\/2014(06)12_bib55","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1359\/JBMR.050601","article-title":"RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis","volume":"20","author":"Stolina","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"1","key":"10.6061\/clinics\/2014(06)12_bib56","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00223-005-0161-1","article-title":"The receptor activator of nuclear factor-kB ligand inhibitor osteoprotegerin is a bone-protective agent in a rat model of chronic renal insufficiency and hyperparathyroidism","volume":"78","author":"Padagas","year":"2006","journal-title":"Calcif Tissue Int"},{"issue":"12","key":"10.6061\/clinics\/2014(06)12_bib57","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1359\/jbmr.060905","article-title":"RANKL inhibition: A novel strategy to decrease femoral head deformity after ischemic necrosis","volume":"21","author":"Kim","year":"2006","journal-title":"J Bone Miner Res"},{"issue":"8","key":"10.6061\/clinics\/2014(06)12_bib58","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s00198-007-0363-7","article-title":"The RANKL inhibitor OPG-Fc increases cortical and trabecular bone mass in intact cynomolgus monkeys","volume":"18","author":"Ominsky","year":"2007","journal-title":"Osteoporos Int"},{"issue":"2","key":"10.6061\/clinics\/2014(06)12_bib59","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1359\/jbmr.2001.16.2.348","article-title":"The effect of a single dose of osteoprotegerin in postmenopausal women","volume":"16","author":"Bekker","year":"2001","journal-title":"J Bone Miner Res"},{"issue":"8","key":"10.6061\/clinics\/2014(06)12_bib61","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrd3244","article-title":"Denosumab","volume":"9","author":"Rizzoli","year":"2010","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.6061\/clinics\/2014(06)12_bib62","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/01.NPR.0000391178.47878.73","article-title":"Denosumab (Prolia): a new option in the treatment of osteoporosis","volume":"36","author":"Belavic","year":"2011","journal-title":"Nurse Pract"},{"issue":"1","key":"10.6061\/clinics\/2014(06)12_bib63","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.bone.2010.10.161","article-title":"Clinical development of anti- RANKL therapies for treatment and prevention of bone metastasis","volume":"48","author":"Lipton","year":"2011","journal-title":"Bone"},{"issue":"2","key":"10.6061\/clinics\/2014(06)12_bib64","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","article-title":"Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial","volume":"43","author":"Miller","year":"2008","journal-title":"Bone"},{"issue":"2","key":"10.6061\/clinics\/2014(06)12_bib65","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.maturitas.2010.02.008","article-title":"Treatment of osteoporosis with denosumab","volume":"66","author":"Lewiecki","year":"2010","journal-title":"Maturitas"},{"issue":"8","key":"10.6061\/clinics\/2014(06)12_bib66","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"issue":"8","key":"10.6061\/clinics\/2014(06)12_bib67","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"N Engl J Med"},{"issue":"4","key":"10.6061\/clinics\/2014(06)12_bib68","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1158\/1078-0432.CCR-05-1933","article-title":"A study of the biological receptor activator of nuclear factor-kB ligant inhibitor, Denosumab, in patients with multiple myeloma or bone metastases from breast cancer","volume":"12","author":"Body","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.6061\/clinics\/2014(06)12_bib69","first-page":"365","article-title":"Drugs for the management of osteoporosis: a review","volume":"51","author":"Khajuria","year":"2011","journal-title":"Rev Bras Reumatol"},{"issue":"8","key":"10.6061\/clinics\/2014(06)12_bib70","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1172\/JCI200317215","article-title":"Role of RANK ligand in mediating increased bone resorption in early postmenopausal women","volume":"111","author":"Eghbali-Fatourechi","year":"2003","journal-title":"J Clin Invest"},{"issue":"2","key":"10.6061\/clinics\/2014(06)12_bib71","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S8756-3282(02)00953-5","article-title":"The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts","volume":"32","author":"Bord","year":"2003","journal-title":"Bone"},{"issue":"12","key":"10.6061\/clinics\/2014(06)12_bib72","first-page":"3458","article-title":"Mechanism of renal calcium conservation with estrogen replacement therapy in women in early postmenopause - a clinical research center study","volume":"80","author":"McKane","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.6061\/clinics\/2014(06)12_bib73","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1210\/jcem-71-5-1288","article-title":"Estrogen preserves a normal intestinal responsiveness to 1,25-dihydroxyvitamin D3 in oophorectomized women","volume":"71","author":"Gennari","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"issue":"18","key":"10.6061\/clinics\/2014(06)12_bib74","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume":"90","author":"Fisher","year":"1998","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.6061\/clinics\/2014(06)12_bib75","first-page":"418","article-title":"Selective estrogen receptor modulators: Clinical spectrum","volume":"20","author":"Cosman","year":"1999","journal-title":"Endocr Rev"},{"issue":"5","key":"10.6061\/clinics\/2014(06)12_bib76","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1634\/theoncologist.5-5-388","article-title":"Raloxifene: A Selective Estrogen Receptor Modulator (SERM) with Multiple Target System Effects","volume":"5","author":"Muchmore","year":"2000","journal-title":"Oncologist"},{"key":"10.6061\/clinics\/2014(06)12_bib77","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.archoralbio.2009.11.001","article-title":"Histomorphometric analysis and immunolocalization of RANKL and OPG during the alveolar healing process in female ovariectomized rats treated with oestrogen or raloxifene","volume":"55","author":"Luvizuto","year":"2010","journal-title":"Arch Oral Biol"},{"issue":"6","key":"10.6061\/clinics\/2014(06)12_bib78","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.bcp.2004.11.030","article-title":"Sodium nitroprusside-induced osteoblast apoptosis is mediated by long chain ceramide and is decreased by raloxifene","volume":"69","author":"Olivier","year":"2005","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"10.6061\/clinics\/2014(06)12_bib79","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S8756-3282(01)00685-8","article-title":"The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro","volume":"30","author":"Taranta","year":"2002","journal-title":"Bone"},{"issue":"9","key":"10.6061\/clinics\/2014(06)12_bib80","doi-asserted-by":"crossref","first-page":"4206","DOI":"10.1210\/jc.2002-021877","article-title":"Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts","volume":"88","author":"Viereck","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.6061\/clinics\/2014(06)12_bib81","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0003-9969(01)00086-3","article-title":"Effects of oestrogen deficiency on osteoclastogenesis in the rat periodontium","volume":"47","author":"Kawamoto","year":"2002","journal-title":"Arch Oral Bio"},{"issue":"3","key":"10.6061\/clinics\/2014(06)12_bib82","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/sj.bjp.0707232","article-title":"Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro","volume":"151","author":"Michael","year":"2007","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.6061\/clinics\/2014(06)12_bib83","first-page":"21","article-title":"Estradiol and Raloxifene induce the proliferation of osteoblasts through G-protein-coupled receptor GPR30","volume":"36","author":"Noda-Seino","year":"2013","journal-title":"J Endocrinol Invest"},{"issue":"19","key":"10.6061\/clinics\/2014(06)12_bib84","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"issue":"6455","key":"10.6061\/clinics\/2014(06)12_bib85","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/366575a0","article-title":"Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid","volume":"366","author":"Brown","year":"1993","journal-title":"Nature"},{"issue":"6","key":"10.6061\/clinics\/2014(06)12_bib86","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.bone.2007.03.017","article-title":"Molecular and cellular mechanisms of the anabolic effect of intermittent PTH","volume":"40","author":"Jilka","year":"2007","journal-title":"Bone"},{"issue":"1","key":"10.6061\/clinics\/2014(06)12_bib87","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11914-010-0006-3","article-title":"Orthopedic uses of teriparatide","volume":"8","author":"Bukata","year":"2010","journal-title":"Curr Osteoporos Rep"},{"issue":"6","key":"10.6061\/clinics\/2014(06)12_bib88","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1359\/jbmr.1999.14.6.960","article-title":"Intermittent parathyroid hormone (1-34) treatment increases callus formation and mechanical strength of healing rat fractures","volume":"14","author":"Andreassen","year":"1999","journal-title":"J Bone Miner Res"},{"issue":"6","key":"10.6061\/clinics\/2014(06)12_bib89","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.bone.2006.09.008","article-title":"Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure","volume":"40","author":"Compston","year":"2007","journal-title":"Bone"},{"issue":"1","key":"10.6061\/clinics\/2014(06)12_bib90","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/jcb.21816","article-title":"Teriparatide (1-34 human PTH) regulation of osterix during fracture repair","volume":"105","author":"Kaback","year":"2008","journal-title":"J Cell Biochem"},{"issue":"11","key":"10.6061\/clinics\/2014(06)12_bib91","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1359\/jbmr.2002.17.11.2038","article-title":"Mechanisms for the enhancement of fracture healing in rats treated with intermittent low-dose human parathyroid hormone (1-34)","volume":"17","author":"Nakajima","year":"2002","journal-title":"J Bone Miner Res"},{"issue":"5","key":"10.6061\/clinics\/2014(06)12_bib92","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.bone.2005.06.013","article-title":"Effects of low-dose, intermittent treatment with recombinant human parathyroid hormone (1-34) on chondrogenesis in a model of experimental fracture healing","volume":"37","author":"Nakazawa","year":"2005","journal-title":"Bone"},{"issue":"1","key":"10.6061\/clinics\/2014(06)12_bib93","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11914-010-0006-3","article-title":"Orthopedic Uses of Teriparatide","volume":"8","author":"Bukata","year":"2010","journal-title":"Curr Osteoporos Rep"},{"issue":"12","key":"10.6061\/clinics\/2014(06)12_bib94","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1359\/jbmr.070724","article-title":"Enhanced chondrogenesis and Wnt signaling in PTH-treated fractures","volume":"22","author":"Kakar","year":"2007","journal-title":"Journal of bone and mineral research. J Bone Miner Res"},{"issue":"5","key":"10.6061\/clinics\/2014(06)12_bib95","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1210\/er.2004-0006","article-title":"Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use","volume":"26","author":"Hodsman","year":"2005","journal-title":"Endocr Rev"},{"issue":"6","key":"10.6061\/clinics\/2014(06)12_bib96","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s00198-009-1004-0","article-title":"Of mice and men: divergent risks of teriparatide-induced osteosarcoma","volume":"21","author":"Subbiah","year":"2010","journal-title":"Osteoporos Int"},{"issue":"20","key":"10.6061\/clinics\/2014(06)12_bib97","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1056\/NEJMoa071408","article-title":"Teriparatide or alendronate in glucocorticoid-induced osteoporosis","volume":"357","author":"Saag","year":"2007","journal-title":"N Engl J Med"},{"issue":"4","key":"10.6061\/clinics\/2014(06)12_bib98","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1080\/01926230490462138","article-title":"Bone neoplasms in F344 rats given teriparatide [rhPTH(1\u201334)] are dependent on duration of treatment and dose","volume":"32","author":"Vahle","year":"2004","journal-title":"Toxicol Pathol"},{"key":"10.6061\/clinics\/2014(06)12_bib99","first-page":"SA435","article-title":"A no observable carcinogenic effect dose level identified in Fischer 344 rats following daily treatment with PTH(1-84) for 2 years: role of the C-terminal PTH receptor?","volume":"19 Supp 1","author":"Wilker","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"2","key":"10.6061\/clinics\/2014(06)12_bib100","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00774-009-0123-1","article-title":"Teriparatide is safe and effectively increases bone biomarkers in institutionalized individuals with osteoporosis","volume":"28","author":"Ryder","year":"2010","journal-title":"J Bone Miner Metab"},{"issue":"1","key":"10.6061\/clinics\/2014(06)12_bib101","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jocd.2008.10.002","article-title":"Active comparator trial of teriparatide vs alendronate for treating glucocorticoid-induced osteoporosis: results from the Hispanic and non-Hispanic cohorts","volume":"12","author":"Losada","year":"2009","journal-title":"J Clin Densitom"},{"issue":"2","key":"10.6061\/clinics\/2014(06)12_bib102","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1359\/jbmr.061111","article-title":"Osteosarcoma and teriparatide","volume":"22","author":"Harper","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.6061\/clinics\/2014(06)12_bib103","first-page":"1","article-title":"Strontium ranelate in postmenopausal osteoporosis treatment: a critical appraisal","volume":"2","author":"Cesareo","year":"2010","journal-title":"Int J Womens Health"},{"issue":"12","key":"10.6061\/clinics\/2014(06)12_bib104","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1136\/ard.2008.094516","article-title":"Strontium ranelate reduces the risk of vertebral fracture in young postmenopausal women with severe osteoporosis","volume":"67","author":"Roux","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.6061\/clinics\/2014(06)12_bib105","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00198-004-1753-8","article-title":"Strontium ranelate: a novel mode of action optimizing bone formation and resorption","volume":"16","author":"Marie","year":"2005","journal-title":"Osteoporos Int"},{"issue":"7","key":"10.6061\/clinics\/2014(06)12_bib106","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/j.1476-5381.2009.00305.x","article-title":"Osteoblasts play key roles in the mechanisms of action of strontium ranelate","volume":"157","author":"Brennan","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.6061\/clinics\/2014(06)12_bib107","first-page":"40-S5-8","article-title":"Strontium ranelate: new insights into its dual mode of action","author":"Marie","year":"2007","journal-title":"Bone"},{"issue":"1","key":"10.6061\/clinics\/2014(06)12_bib108","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.bone.2007.08.043","article-title":"Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro","volume":"42","author":"Bonnelye","year":"2008","journal-title":"Bone"},{"issue":"1","key":"10.6061\/clinics\/2014(06)12_bib109","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0014-2999(02)02040-X","article-title":"In vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differentiation","volume":"450","author":"Baron","year":"2002","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"10.6061\/clinics\/2014(06)12_bib110","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1359\/jbmr.2003.18.6.1082","article-title":"S 12911-2 Inhibits osteoclastic bone resorption in vitro","volume":"18","author":"Takahashi","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.6061\/clinics\/2014(06)12_bib111","first-page":"M237","article-title":"Extracellular concentrations of strontium directly stimulates osteoclast apoptosis","volume":"18","author":"Mentaverri","year":"2003","journal-title":"J Bone Min Res"},{"issue":"3","key":"10.6061\/clinics\/2014(06)12_bib112","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.bcp.2007.04.020","article-title":"The calcium-sensing receptor (CaR) is involved in strontium ranelate-induced osteoblast proliferation","volume":"74","author":"Chattopadhyay","year":"2007","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"10.6061\/clinics\/2014(06)12_bib113","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.bbrc.2007.01.120","article-title":"Induction of a program gene expression during osteoblast differentiation with strontium ranelate","volume":"355","author":"Zhu","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"issue":"1-2","key":"10.6061\/clinics\/2014(06)12_bib114","first-page":"25","article-title":"Osteoblast Differentiation and Bone Formation Gene Expression in Strontium-inducing Bone Marrow Mesenchymal Stem Cell","volume":"53","author":"Sila-Asna","year":"2007","journal-title":"Kobe J Med Sci"},{"issue":"1","key":"10.6061\/clinics\/2014(06)12_bib115","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1166\/jnn.2012.5125","article-title":"Evaluation of osteoinduction and proliferation on nano-Sr-HAP: a novel orthopedic biomaterial for bone tissue regeneration","volume":"12","author":"Hao","year":"2012","journal-title":"J Nanosci Nanotechnol"},{"issue":"4","key":"10.6061\/clinics\/2014(06)12_bib116","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s10856-011-4264-0","article-title":"The effect of strontium incorporation in hydroxyapatite on osteoblasts in vitro","volume":"22","author":"Ni","year":"2011","journal-title":"J Mater Sci Mater Med"},{"key":"10.6061\/clinics\/2014(06)12_bib117","doi-asserted-by":"crossref","first-page":"130","DOI":"10.22203\/eCM.v021a11","article-title":"Effects of strontium-doped bioactive glass on the differentiation of cultured osteogenic cells","volume":"21","author":"Isaac","year":"2011","journal-title":"Eur Cell Mater"},{"issue":"3","key":"10.6061\/clinics\/2014(06)12_bib118","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s10856-011-4247-1","article-title":"In vitro study in stimulating the secretion of angiogenic growth factors of strontium-doped calcium polyphosphate for bone tissue engineering","volume":"22","author":"Liu","year":"2011","journal-title":"J Mater Sci Mater Med"},{"issue":"2","key":"10.6061\/clinics\/2014(06)12_bib119","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.actbio.2010.08.031","article-title":"Effects of strontium in modified biomaterials","volume":"7","author":"Zhang","year":"2011","journal-title":"Acta Biomater"},{"key":"10.6061\/clinics\/2014(06)12_bib120","doi-asserted-by":"crossref","first-page":"865291","DOI":"10.1155\/2012\/865291","article-title":"Osteodifferentiation of human preadipocytes induced by strontium released from hydrogels","volume":"2012","author":"Nardone","year":"2012","journal-title":"Int J Biomater"},{"issue":"5","key":"10.6061\/clinics\/2014(06)12_bib121","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1172\/JCI28551","article-title":"Regulation of bone mass by Wnt signalling","volume":"116","author":"Krishnan","year":"2006","journal-title":"J Clin Invest"},{"issue":"1-2","key":"10.6061\/clinics\/2014(06)12_bib122","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11154-006-9002-4","article-title":"Wnt signaling and osteoblastogenesis","volume":"7","author":"Bodine","year":"2006","journal-title":"Rev Endocr Metab Disord"},{"issue":"11","key":"10.6061\/clinics\/2014(06)12_bib123","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1359\/jbmr.070721","article-title":"Patients with high bone mass phenotype exhibit enhanced osteoblast differentiation and inhibition of adipogenesis of human mesenchymal stem cells","volume":"22","author":"Qiu","year":"2007","journal-title":"J Bone Miner Res"},{"issue":"6","key":"10.6061\/clinics\/2014(06)12_bib124","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1210\/en.2007-0270","article-title":"Targeting the Wnt\/beta-catenin pathway to regulate bone formation in the adult skeleton","volume":"148","author":"Baron","year":"2007","journal-title":"Endocrinology"},{"issue":"11","key":"10.6061\/clinics\/2014(06)12_bib125","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1210\/me.2007-0259","article-title":"Gone with the Wnts: beta-catenin, T-cell factor, forkhead box O, and oxidative stress in age-dependent diseases of bone, lipid, and glucose metabolism","volume":"21","author":"Manolagas","year":"2007","journal-title":"Molecular Endocrinology"},{"issue":"48","key":"10.6061\/clinics\/2014(06)12_bib126","doi-asserted-by":"crossref","first-page":"17406","DOI":"10.1073\/pnas.0505259102","article-title":"Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice","volume":"102","author":"Cl\u00e9ment-Lacroix","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.6061\/clinics\/2014(06)12_bib127","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1359\/jbmr.060316","article-title":"Orally bioavailable GSK-3alpha\/beta dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo","volume":"21","author":"Kulkarni","year":"2006","journal-title":"J Bone Miner Res"},{"issue":"1","key":"10.6061\/clinics\/2014(06)12_bib128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EJE-11-0132","article-title":"Osteoblasts in osteoporosis: past, emerging, and future anabolic targets","volume":"165","author":"Marie","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.6061\/clinics\/2014(06)12_bib129","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1359\/jbmr.080216","article-title":"Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength","volume":"23","author":"Li","year":"2008","journal-title":"J Bone Miner Res"},{"issue":"1","key":"10.6061\/clinics\/2014(06)12_bib130","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/dvdy.22181","article-title":"Wnt modulators in the biotech pipeline","volume":"239","author":"Rey","year":"2010","journal-title":"Dev Dyn"},{"issue":"4","key":"10.6061\/clinics\/2014(06)12_bib131","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1172\/JCI38973","article-title":"Wnt therapy for bone loss: golden goose or Trojan horse?","volume":"119","author":"Enders","year":"2009","journal-title":"J Clin Invest"},{"issue":"6","key":"10.6061\/clinics\/2014(06)12_bib132","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1359\/jbmr.060311","article-title":"Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass","volume":"21","author":"Morvan","year":"2006","journal-title":"J Bone Miner Res"},{"issue":"4","key":"10.6061\/clinics\/2014(06)12_bib133","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.bone.2006.03.017","article-title":"Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia","volume":"39","author":"Li","year":"2006","journal-title":"Bone"},{"issue":"2","key":"10.6061\/clinics\/2014(06)12_bib134","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cmet.2009.12.007","article-title":"Suppression of Wnt signaling by Dkk1 attenuates PTH-mediated stromal cell response and new bone formation","volume":"11","author":"Guo","year":"2010","journal-title":"Cell Metab"},{"issue":"4","key":"10.6061\/clinics\/2014(06)12_bib135","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1359\/jbmr.081206","article-title":"Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis","volume":"24","author":"Li","year":"2009","journal-title":"J Bone Miner Res"},{"issue":"1","key":"10.6061\/clinics\/2014(06)12_bib136","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jbmr.173","article-title":"Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody","volume":"26","author":"Padhi","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"5","key":"10.6061\/clinics\/2014(06)12_bib137","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/jbmr.14","article-title":"Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength","volume":"25","author":"Ominsky","year":"2010","journal-title":"J Bone Miner Res"},{"issue":"12","key":"10.6061\/clinics\/2014(06)12_bib138","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1002\/jbmr.182","article-title":"Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats","volume":"25","author":"Li","year":"2010","journal-title":"J Bone Miner Res"},{"issue":"2","key":"10.6061\/clinics\/2014(06)12_bib139","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s11420-009-9109-8","article-title":"Recent advances toward the clinical application of PTH (1-34) in fracture healing","volume":"5","author":"Cipriano","year":"2009","journal-title":"HSS J"},{"issue":"7","key":"10.6061\/clinics\/2014(06)12_bib140","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1359\/JBMR.050309","article-title":"Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters","volume":"20","author":"Arlot","year":"2005","journal-title":"Bone Miner Res"},{"issue":"2","key":"10.6061\/clinics\/2014(06)12_bib141","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jocd.2011.11.006","article-title":"Hip cortical thickness assessment in postmenopausal women with osteoporosis and strontium ranelate effect on hip geometry","volume":"15","author":"Briot","year":"2012","journal-title":"J Clin Densitom"}],"container-title":["Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593222009085?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593222009085?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/clinics.org.br\/uploads\/artigos\/cln-69-06\/cln-69-06-438.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T06:54:23Z","timestamp":1761720863000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1807593222009085"},"secondary":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_abstract&pid=S1807-59322014000600438&lng=en&nrm=iso","label":"SCIELO"},{"URL":"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4050321\/?report=classic","label":"PMC"}]},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":140,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S1807593222009085"],"URL":"https:\/\/doi.org\/10.6061\/clinics\/2014(06)12","relation":{},"ISSN":["1807-5932"],"issn-type":[{"value":"1807-5932","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological management of osteogenesis","name":"articletitle","label":"Article Title"},{"value":"Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.6061\/clinics\/2014(06)12","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 CLINICS. Published by Elsevier Spain","name":"copyright","label":"Copyright"}]}}